Unlocking a Potent New Avenue for Brain Cancer Treatment: The Synthesis and Promise of Verticillin A
For decades,the complex molecular structure of verticillin A,a natural product exhibiting promising anti-cancer properties,remained a formidable challenge for chemists. Now, a team led by Professor Mohammad Movassaghi at Cornell University has achieved a groundbreaking total synthesis of this elusive molecule, paving the way for the growth of novel therapies, especially for aggressive pediatric brain tumors like Diffuse Midline Glioma (DMG). This achievement, detailed in recent research, isn’t just a triumph of synthetic chemistry; it’s a critical step towards translating a natural compound’s potential into tangible patient benefit.
The Decades-Long Pursuit of Verticillin A
Natural products have historically been a cornerstone of pharmaceutical revelation, providing the blueprints for many life-saving drugs. However, obtaining sufficient quantities of these compounds from natural sources is often impractical, hindering complete research and clinical development. Total synthesis – the complete chemical construction of a complex molecule from simpler building blocks – offers a solution, but only if the synthesis is efficient and scalable.
Verticillin A presented an exceptional hurdle. “The inherent instability of the molecule greatly limits the window of possibility that you have in terms of doing chemical transformations,” explains Movassaghi. The molecule’s delicate structure, rich in sensitive functional groups, meant even incremental progress in synthetic methodology couldn’t overcome its fragility. Years of effort were stymied by the compound’s tendency to degrade during the synthesis process.
A Revolutionary Shift in Synthetic strategy
The team’s breakthrough stemmed from a fundamental rethinking of the synthetic route. Previous attempts to synthesize a related molecule, (+)-11,11′-dideoxyverticillin A, involved a late-stage dimerization – joining two identical halves to form the complete structure – followed by the formation of crucial carbon-sulfur bonds. This approach proved disastrous when applied to verticillin A. The timing was critical.
“What we learned was the timing of the events is absolutely critical. We had to substantially change the order of the bond-forming events,” Movassaghi emphasizes.
The new strategy begins with beta-hydroxytryptophan, an amino acid derivative, and meticulously builds the structure in a 16-step process. This involves carefully adding functional groups – alcohols, ketones, and amides – while rigorously controlling stereochemistry (the 3D arrangement of atoms) at each stage. A key innovation was the early introduction of carbon-sulfur bonds,but these were initially “masked” as protected sulfides to prevent premature degradation. These protective groups were later removed to restore the disulfide functionality after the challenging dimerization step.
This dimerization itself is a remarkable feat,bringing together complex molecular fragments with a dense array of functional groups and precise stereochemical control. The success highlights the team’s mastery of advanced synthetic techniques and their ability to overcome seemingly insurmountable challenges.
Early Promise Against diffuse Midline glioma
With a reliable supply of verticillin A now available, researchers at Dana-Farber Cancer Institute, led by Dr. Heng Qi, began exploring its therapeutic potential. Initial tests focused on Diffuse Midline Glioma (DMG), a devastating brain tumor that disproportionately affects children and young adults, with limited effective treatment options.
The results were encouraging. Verticillin A derivatives exhibited the strongest effects in DMG cell lines with high levels of EZHIP, a protein involved in DNA methylation. EZHIP has emerged as a promising drug target for DMG, and the verticillin derivatives appear to modulate its activity, leading to increased DNA methylation and ultimately, programmed cell death in cancer cells.
Specifically, N-sulfonylated (+)-11,11′-dideoxyverticillin A and N-sulfonylated verticillin A demonstrated the most potent activity. N-sulfonylation, the addition of a sulfur-oxygen functional group, enhances the molecule’s stability, improving its potential as a drug candidate.
“The natural product itself is not the most potent, but it’s the natural product synthesis that brought us to a point where we can make these derivatives and study them,” Movassaghi notes, underscoring the importance of the synthetic achievement.
Looking Ahead: From Lab Bench to Clinical Submission
The Dana-Farber team is now focused on elucidating the precise mechanism of action of the verticillin derivatives and plans to validate their efficacy in animal models of pediatric brain cancers. Furthermore, they are conducting broad-spectrum screening of these molecules against over 800 cancer cell lines to identify potential applications beyond DMG.
“Identifying the potential targets of these compounds will play a critical role in further understanding their mechanism of action, and more importantly, will help optimize the compounds…to be
Related reading